市場調查報告書
商品編碼
1323307
消費者保健(CHC)市場檢討:2023年中間報告Mid-2023 CHC Review |
本報告提供消費者保健(CHC)市場相關調查,彙整各市場分類的銷售額實際成果和趨勢,前12名市場(美國,中國,德國,巴西,義大利,印度等)的最新趨勢,及今後的短期及2027年及到2032年為止的長期預測等資料。
The report features the latest MAT Q2 2023 sales data from our dedicated DB6 database, including topline historical sales globally, by region, country and category, short-term forecasts to 2023-24 and long-term forecasts to 2027 & 2032.
Find out the very latest global, regional and market-level trends in CHC Access the newest sales data, freshly published by DB6 Read fresh analysis of category trends, brand activity and regulatory updates Get your hands on the most up-to-date short-term forecasts
|
|
Nicholas Hall's “Mid-2023 CHC Review”, charts the very latest CHC sales, growth drivers and forecasts in a succinct topical review.
Over 90 detail-packed pages, it probes the most important CHC market influences globally, across categories and individual markets, while casting an eye to the future.
The report features the latest MAT Q2 2023 sales data from our dedicated DB6 database, including topline historical sales globally, by region, country and category, short-term forecasts to 2023-24 and long-term forecasts to 2027 & 2032.
Featuring sales for the 12-month period ending June 2023, plus y-o-y growth rates, the report includes over 60 unique sales charts. Historical growth rates 2019-22 are included to help chronicle performance fluctuations over time.
Global Overview delves into the CHC market's performance and tracks the latest happenings in Switch, Innovation, M&A and beyond.
Covering all six major categories in turn, Category Trends charts the factors impacting Analgesics, CCA, GIs, VMS, Derma and Lifestyle CHC, casting the spotlight on individual subcategories.
Core Markets assesses the most recent developments in each of the Top 12 markets (including USA, China, Germany, Brazil, Italy, India and more), appraising performances and trends category by category.
Evaluating the future of CHC, the Outlook chapter considers the prospects & challenges facing CHC players, alongside short- and long-term forecast sales.
1including historical growth rates; 2including CAGR 22/18.